Faculty

Back to Index
Alan S. Wayne, MD
Professor of Pediatrics (Clinical Scholar)
Interim Director of The Norris Comprehensive Cancer Center
Pediatrics
CHL Mail Stop 54 Off Campus Los Angeles
+1 323 361 2121

Overview

Alan S. Wayne, M.D. is the Associate Director for Pediatric Oncology at the USC Norris Comprehensive Cancer Center, Professor of Pediatrics at the Keck School of Medicine of USC, the Director of the Children's Center for Cancer & Blood Diseases at CHLA, the Head of the Division of Hematology, Oncology and Blood & Marrow Transplantation in the Department of Pediatrics, and the Director of the Pediatric Hematology-Oncology Fellowship Training Program. As the head of the division, Dr. Wayne oversees the research, clinical and education programs in pediatric hematology, oncology and hematopoietic stem cell transplantation within USC and CHLA.

His primary research efforts are directed towards the development of new treatment approaches for leukemias and lymphomas, with a primary focus on relapsed/refractory acute lymphoblastic leukemia. He develops and conducts collaborative laboratory, translational, and clinical investigations, including bench-to-bedside development of targeted, immune-based and cellular therapies, investigator-initiated clinical trials and industry-sponsored studies. Dr. Wayne serves as the Medical Director of the Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium, which is a multinational clinical trials group that conducts Phase I and II trials.

Publications

Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles. 2017; 6(1):1294368. View in: PubMed

Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016 Nov; 63(11):1943-8. View in: PubMed

Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design. Clin Cancer Res. 2016 Oct 1; 22(19):4913-4922. View in: PubMed

Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse. Biol Blood Marrow Transplant. 2016 Sep 12. View in: PubMed

Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance. J Pediatr Hematol Oncol. 2016 Jul; 38(5):345-9. View in: PubMed

Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®): Results From a Phase I Study in Children, Adolescents, and Young Adults With Refractory Solid Tumors or Leukemias. Pediatr Blood Cancer. 2016 Jun; 63(6):997-1005. View in: PubMed

Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins. Mol Cancer Ther. 2016 May; 15(5):1053-62. View in: PubMed

Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. Invest New Drugs. 2016 Feb; 34(1):61-5. View in: PubMed

Improving access to novel agents for childhood leukemia. Cancer. 2015 Jun 15; 121(12):1927-36. View in: PubMed

Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015 Jun; 62(6):964-9. View in: PubMed

Is another antibody conjugate against ALL needed? Lancet Haematol. Is another antibody conjugate against ALL needed? Lancet Haematol. 2015 Mar; 2(3):e87-8. View in: PubMed

Abnormal bone marrow histopathology in paediatric mastocytosis. Br J Haematol. 2015 Mar; 168(6):865-73. View in: PubMed

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015 Feb 7; 385(9967):517-28. View in: PubMed

Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell-depleted stem cell transplantation. Blood. 2015 Jan 29; 125(5):784-92. View in: PubMed

Feasibility of treating post-transplantation minimal residual disease in children with acute leukemia. Biol Blood Marrow Transplant. 2014 Jul; 20(7):1000-7. View in: PubMed

Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Jul; 20(7):1033-9. View in: PubMed

Immunotoxins for leukemia. Blood. 2014 Apr 17; 123(16):2470-7. View in: PubMed

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2014 Jan; 20(1):4-13. View in: PubMed

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part II. Autologous Transplantation-Novel Agents and Immunomodulatory Strategies. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1661-9. View in: PubMed

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1537-45. View in: PubMed

Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy. 2013 Nov; 15(11):1406-15. View in: PubMed

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1534-6. View in: PubMed

Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8. Leuk Res. 2013 Nov; 37(11):1551-6. View in: PubMed

A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene. J Biol Chem. 2013 Apr 26; 288(17):12305-12. View in: PubMed

Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype. Pharmacotherapy. 2013 Mar; 33(3):e19-22. View in: PubMed

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013 Feb 14; 121(7):1165-74. View in: PubMed

Immunotherapy for pediatric leukemia. Front Oncol. 2013; 3:166. View in: PubMed

Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012 Nov 1; 30(31):3876-83. View in: PubMed

Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012 Nov 1; 120(18):3635-46. View in: PubMed

Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges. Am J Hematol. 2012 Sep; 87(9):916-22. View in: PubMed

Pretransplant MRD: the light is yellow, not red. Blood. 2012 Jul 12; 120(2):244-6. View in: PubMed

Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant. 2012 May; 18(5):698-707. View in: PubMed

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc Natl Acad Sci U S A. 2012 May 1; 109(18):6898-903. View in: PubMed

Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency. J Allergy Clin Immunol. 2012 Mar; 129(3):762-769. e1. View in: PubMed

Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain. Blood. 2012 Feb 23; 119(8):1848-55. View in: PubMed

Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk. 2012 Feb; 12(1):20-5. View in: PubMed

Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. PLoS One. 2012; 7(12):e52655. View in: PubMed

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res. 2011 Oct 15; 71(20):6300-9. View in: PubMed

Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood. 2011 Sep 8; 118(10):2688-94. View in: PubMed

Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 2; 117(22):5835-49. View in: PubMed

Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:79-81. View in: PubMed

National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54. View in: PubMed

Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom. 2011 Mar; 80(2):83-90. View in: PubMed

Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother. 2011 Mar; 34(2):187-95. View in: PubMed

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503. View in: PubMed

Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010 Nov; 95(11):1873-9. View in: PubMed

NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46. View in: PubMed

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211. View in: PubMed

Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol. 2010 Aug; 150(3):352-8. View in: PubMed

Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):563-4. View in: PubMed

The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010 Apr 15; 115(15):3017-24. View in: PubMed

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15; 16(6):1894-903. View in: PubMed

Immune-based therapeutics for pediatric cancer. Expert Opin Biol Ther. 2010 Feb; 10(2):163-78. View in: PubMed

Hematopoietic stem cell transplantation for leukemia. Pediatr Clin North Am. 2010 Feb; 57(1):1-25. View in: PubMed

Immunotherapy of childhood cancer: from biologic understanding to clinical application. Curr Opin Pediatr. 2010 Feb; 22(1):2-11. View in: PubMed

Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemia. Pediatr Blood Cancer. 2010 Jan; 54(1):173-5. View in: PubMed

Extracorporeal photo-apheresis for the treatment of steroid-resistant graft versus host disease. Transfus Apher Sci. 2009 Dec; 41(3):209-16. View in: PubMed

Application of immunotherapy in pediatric leukemia. Curr Hematol Malig Rep. 2009 Jul; 4(3):159-66. View in: PubMed

Progress in the curative treatment of childhood hematologic malignancies. J Natl Cancer Inst. 2008 Sep 17; 100(18):1271-3. View in: PubMed

Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients. J Proteomics. 2008 Apr 30; 71(1):61-70. View in: PubMed

Sibling stem cell donor experiences at a single institution. Psychooncology. 2008 Mar; 17(3):304-7. View in: PubMed

Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and therapy. Pediatr Infect Dis J. 2008 Mar; 27(3):265-8. View in: PubMed

Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol. 2007 Nov; 110(5):1041-9. View in: PubMed

Thromboembolic events in children and young adults with pediatric sarcoma. J Clin Oncol. 2007 Apr 20; 25(12):1519-24. View in: PubMed

The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions. Transfusion. 2007 Mar; 47(3):545-50. View in: PubMed

Hematopoietic stem cell donation in children: a review of the sibling donor experience. J Psychosoc Oncol. 2007; 25(1):45-66. View in: PubMed

Psychotropic medication use in pediatric patients with cancer. Arch Pediatr Adolesc Med. 2006 Aug; 160(8):818-22. View in: PubMed

Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006 Apr; 12(4):375-96. View in: PubMed

Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 2):22-30. View in: PubMed

Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol. 2005 Jul 20; 23(21):4735-41. View in: PubMed

Two novel CHS1 (LYST) mutations: clinical correlations in an infant with Chediak-Higashi syndrome. Mol Genet Metab. 2005 Jun; 85(2):125-32. View in: PubMed

Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. J Clin Oncol. 2004 Sep 15; 22(18):3798-804. View in: PubMed

Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens. Transfusion. 2004 Feb; 44(2):229-38. View in: PubMed

Allogeneic hematopoietic stem cell transplantation for myeloproliferative disorders and myelodysplastic syndromes. Hematol Oncol Clin North Am. 2003 Oct; 17(5):1243-60. View in: PubMed

Powered bySC CTSI